Australia to investigate two deaths for possible links to COVID-19 vaccine | Inquirer News

Australia to investigate two deaths for possible links to COVID-19 vaccine

/ 09:05 AM April 29, 2021

Australia to investigate two deaths for possible links to COVID-19 vaccine

A healthcare professional administers a dose of the Pfizer coronavirus disease (COVID-19) vaccine to Dr. Chris Quinn as high-risk workers receive the first vaccines in the state of Victoria’s rollout of the program, in Melbourne, Australia, February 22, 2021. REUTERS/Sandra Sanders

SYDNEY Australia’s medicines regulator will investigate two deaths for possible links to the COVID-19 vaccine, raising fresh concerns as the country seeks to accelerate an immunization program that has widely missed its initial vaccination targets.

“All reports … of death following vaccination are reviewed to assess the likelihood that the vaccine contributed to the event or medical condition that led to a fatal outcome,” the Therapeutic Goods Administration (TGA) said on Thursday.

Article continues after this advertisement

Two men died in the country’s most populous state of New South Wales (NSW) days after getting their coronavirus vaccine shots, Australian media reported.

FEATURED STORIES

A 71-year-old man with several underlying health conditions died days after getting AstraZeneca’s vaccine, Seven News reported. A 55-year-old man died eight days after getting his vaccine, a regional newspaper in NSW’s northwest town of Tamworth said in a report, citing his family.

The reporting of an adverse event after vaccination does not mean it was caused by the doses, TGA said in an emailed reply. It did not specify when the deaths happened, citing patient confidentiality reasons, or the type of shots they received.

Article continues after this advertisement

Australia’s immunization drive includes AstraZeneca and Pfizer vaccines but earlier this month authorities abandoned a goal to vaccinate its near 26 million population by the end of 2021 after finding possible links between the AstraZeneca vaccine and blood clots.

Article continues after this advertisement

Australia, which had banked on the AstraZeneca vaccine for the majority of its shots, recommended the doses should only be given to people above 50 years, throwing its vaccination program into disarray.

Article continues after this advertisement

Two weeks ago, the country reported its first death from blood clots linked to the AstraZeneca vaccine after the medicines regulator said a 48-year-old woman’s fatality was “likely” linked to the shot.

Australia has largely avoided the high COVID-19 numbers seen in other developed countries, with just over 29,700 cases and 910 deaths since the pandemic began, but its vaccination rollout has hit several roadblocks.

Article continues after this advertisement

More than 2 million total vaccine doses have been administered as of Tuesday, far short of the 4 million pledged by the end of March.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: Australia, COVID-19, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.